Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT02721979
Phase
PHASE2
Status
Terminated

Conditions

  • Prostate Adenocarcinoma

Eligibility Criteria

Sex
MALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apalutamide — DRUG
    Given PO
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Questionnaire Administration — OTHER
    Ancillary studies

Study Details

This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells.

Key Dates

Start date
Nov 2, 2017
Status verified
Feb 2023
Primary completion
Feb 12, 2020
Completion
Nov 30, 2021

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (apalutamide)
    Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate [ Time Frame: At 90 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109-

Find similar trials in Seattle, WA

By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies